CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 42 enrolled
Drug / intervention
Etoricoxib (Arcoxia)drug
Likely dose
Etoricoxib (Arcoxia) 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01022190
NCT01022190Phase 4Completed
CompareCT.gov

Effect of Etoricoxib (Arcoxia) in Preventing Heterotopic Ossification After Total Hip Arthroplasty

Radboud University Medical Center·interventional·Posted Dec 1, 2009·Updated Sep 9, 2013

In Brief

A Phase 4 clinical trial evaluating Etoricoxib (Arcoxia) for Ossification, Heterotopic. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The purpose of the study is to determine whether Arcoxia is effective in preventing heterotopic ossification after total hip arthroplasty.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOssification, Heterotopic
CountriesNetherlands
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 1, 2009
Enrollment StartDec 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.6 years ago

Interventions

Etoricoxib (Arcoxia)drug

Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days